Scarica l'app Stockscreener
83.06
5.70%
-4.9694
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GH Giù?
Forum
Previsione
Precedente Chiudi:
$88.03
Aprire:
$86.33
Volume 24 ore:
1.19M
Relative Volume:
0.61
Capitalizzazione di mercato:
$10.91B
Reddito:
$902.57M
Utile/perdita netta:
$-398.79M
Rapporto P/E:
-25.85
EPS:
-3.2131
Flusso di cassa netto:
$-274.52M
1 W Prestazione:
-10.34%
1M Prestazione:
-19.22%
6M Prestazione:
+51.21%
1 anno Prestazione:
+92.59%
Intervallo 1D:
$82.26
$87.21
Intervallo di 1 settimana:
$82.26
$93.00
Portata 52W:
$36.36
$120.74
Guardant Health Inc Stock (GH) Company Profile
Nome
Guardant Health Inc
Settore
Industria
Telefono
855-698-8887
Indirizzo
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
83.17 | 11.55B | 902.57M | -398.79M | -274.52M | -3.2131 |
|
TMO
Thermo Fisher Scientific Inc
|
475.77 | 184.15B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
187.82 | 137.93B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
577.77 | 47.82B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.89 | 32.62B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
288.01 | 29.19B | 3.17B | 642.63M | 516.49M | 10.77 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-20 | Reiterato | Canaccord Genuity | Buy |
| 2026-02-17 | Iniziato | Robert W. Baird | Outperform |
| 2026-01-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-09-25 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | Ripresa | Wells Fargo | Overweight |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-28 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-24 | Ripresa | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-11-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Iniziato | Craig Hallum | Buy |
| 2022-10-06 | Iniziato | Stephens | Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-04-28 | Ripresa | BTIG Research | Buy |
| 2022-02-24 | Reiterato | Canaccord Genuity | Buy |
| 2022-02-24 | Reiterato | Citigroup | Buy |
| 2022-02-24 | Reiterato | Cowen | Outperform |
| 2022-02-24 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-24 | Reiterato | SVB Leerink | Outperform |
| 2022-02-24 | Reiterato | Stifel | Buy |
| 2022-02-24 | Reiterato | Wells Fargo | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-11 | Iniziato | Stifel | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-06-12 | Iniziato | BTIG Research | Buy |
| 2020-02-21 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-08-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-04-16 | Iniziato | Canaccord Genuity | Buy |
| 2019-04-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Reiterato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | JP Morgan | Overweight |
| 2018-10-29 | Iniziato | William Blair | Outperform |
Mostra tutto
Guardant Health Inc Borsa (GH) Ultime notizie
Quest Diagnostics Expands Preventive Reach With Shield Colorectal Blood Test - simplywall.st
Capital International Investors Sells 287,217 Shares of Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Guardant Health at Leerink Global Healthcare: Strategic Growth and Partnerships - Investing.com Canada
Guardant Health's Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics - National Today
Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics - Yahoo Finance
Hidalgo Medina sells Guardant Health (GH) shares for $118,996 By Investing.com - Investing.com India
Hidalgo Medina sells Guardant Health (GH) shares for $118,996 - Investing.com
Guardant Health (NASDAQ:GH) Director Medina Manuel Hidalgo Sells 1,300 Shares - MarketBeat
Victory Capital Management Inc. Cuts Stake in Guardant Health, Inc. $GH - MarketBeat
Rhenman & Partners Asset Management AB Makes New Investment in Guardant Health, Inc. $GH - MarketBeat
How geopolitical risks impact Guardant Health Inc. (5GH) stockWeekly Trade Recap & Fast Exit/Entry Strategy Plans - Naître et grandir
Guardant Health Tour Highlights Colorectal Test Uptake And Valuation Gap - Yahoo Finance
BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now? - Finviz
TEM's Diagnostics Arm Expanding Rapidly: What's Driving the Growth? - Yahoo Finance
Legato Capital Management LLC Has $677,000 Position in Guardant Health, Inc. $GH - MarketBeat
Amova Asset Management Americas Inc. Has $47.12 Million Position in Guardant Health, Inc. $GH - MarketBeat
ARK Investment Management LLC Sells 2,028,263 Shares of Guardant Health, Inc. $GH - MarketBeat
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH) and 908 Devices (MASS) - The Globe and Mail
Guardant Health Targets Early Detection Growth With New Partner And Acquisition - simplywall.st
Shield mobile tour brings FDA-approved screening to 100 communities, Guardant Health announces - Traders Union
Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America - Guardant Health
Segall Bryant & Hamill LLC Increases Stock Position in Guardant Health, Inc. $GH - MarketBeat
Guardant Health Launches Coast-to-Coast Screening Tour, Bringing - GuruFocus
Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened - Guardant Health
GH Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Intech Investment Management LLC Has $3.19 Million Stock Holdings in Guardant Health, Inc. $GH - MarketBeat
TD Asset Management Boosts Guardant Health Holdings - National Today
Guardant Health (GH) director acquires 154 shares via RSU vesting - Stock Titan
Guardant Health, Inc. (GH) Stock Analysis: A 41% Upside Potential With Strong Buy Ratings - DirectorsTalk Interviews
Does Guardant’s 2026 Outlook And Shelf Filing Reshape The Bull Case For Guardant Health (GH)? - simplywall.st
TD Asset Management Inc Boosts Holdings in Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (GH) Strengthens Health Technology Portfolio with MetaSight Diagnostics Acquisition - Bitget
TD Cowen Health Care Conference - marketscreener.com
Guardant Health (GH) Is Down 8.9% After Issuing 2026 Guidance And New Equity Shelf Registration – Has The Bull Case Changed? - Yahoo Finance
Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know - The Globe and Mail
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ChartMill
Erste Asset Management GmbH Buys 66,617 Shares of Guardant Health, Inc. $GH - MarketBeat
Colon cancer screening expands with simple blood test as cases rise among under-50s - WLUK
Guardant Health (GH) Gained from Better-Than-Expected Results - Insider Monkey
Guardant Health Stock Hits Day Low at $94.62 Amid Price Pressure - Markets Mojo
Guardant Health, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:GH) 2026-02-25 - Seeking Alpha
Guardant Health Stock Hits Day Low of $93.79 Amid Price Pressure - Markets Mojo
Single‑Reference Disclosures and the Motivation‑to‑Combine Requirement - The National Law Review
Liquidity Mapping Around (GH) Price Events - Stock Traders Daily
Piper Sandler Raises Guardant Health (GH) Price Target to $130 | - GuruFocus
Vanguard Group Inc. Reduces Position in Guardant Health, Inc. $GH - MarketBeat
Guardant Health acquires Israeli healthtech MetaSight for up to $150M - MSN
Guardant Health pushes for AI-driven oncology breakthroughs at Cancer 2035 - Traders Union
Guardant Health slides as investors digest Q4 results and a risk-off tape - Quiver Quantitative
Guardant Health, Inc. (GH) Stock Analysis: A 26.53% Upside Potential in the Precision Oncology Market - DirectorsTalk Interviews
Guardant Health Inc Azioni (GH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.42%
0.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):